The aforementioned studies demonstrate the importance of various molecules in OSA progression in a patient relevant context and provide justification for the development and use of certain targeted therapies [i.e., tyrosine kinase receptor inhibitors (81, 82) and HER2-targeting Listeria (83)]. This evidence concerns the gene ERBB2 and obstructive sleep apnea syndrome.